一分钟看懂
这是一项关于小细胞肺癌的II 期研究，登记的药物或干预包括ABBV-706；Atezolizumab；Etoposide；Carboplatin；Lurbinectedin，当前状态为招募中。登记地点显示中国北京、郑州、武汉、南昌等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
ABBV-706；Atezolizumab；Etoposide；Carboplatin；Lurbinectedin · II 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Cancer Hospital - Chinese Academy of Medical Sciences /ID# 277167 · 北京
- Henan Cancer Hospital /ID# 277059 · 郑州
- Union Hospital Tongji Medical College /ID# 277912 · 武汉
- The First affiliated hospital of Nanchang University /ID# 277247 · 南昌
- Shanghai East Hospital /ID# 277111 · 上海
- Shanghai Pulmonary Hospital /ID# 276960 · 上海
- West China Hospital of Sichuan University /ID# 277852 · 成都
公开的入选条件
- * Diagnosis of histologically or cytologically confirmed extensive stage small cell lung cancer (ES-SCLC) requiring treatment with first line therapy.
- * Have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1 during the screening period prior to the first dose of study treatment.
- * Have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST v1.1).
- * Suspected brain metastases at screening should have a computed tomography (CT)/ magnetic resonance imaging (MRI) of the brain prior to study entry.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT07155174；登记信息更新于 2026-09-11。